Breaking News Instant updates and real-time market news.

SQM

SQM

$23.75

-1.15 (-4.62%)

, ALB

Albemarle

$64.60

-0.68 (-1.04%)

14:17
11/13/19
11/13
14:17
11/13/19
14:17

Lithium suppliers fall amid inventory glut in China, 'weak' electric car sales

Shares of Lithium makers including SQM (SQM), Albemarle (ALB), Livent (LTHM), and FMC (FMC) are lower following an Albemarle downgrade by Citi analyst P.J. Juvekar. ELEVATED LITHIUM SUPPLY: Citi analyst P.J. Juvekar downgraded Albemarle to Sell from Neutral with a price target of $58, down from $62. The analyst said he sees elevated inventory in lithium with ~30 kt of surplus carbonate inventory in China. Further, destocking could take another six months or more given "weak" China new electric vehicle sales on the June subsidy cut and the possibility of another subsidy cut in 2020, Juvekar told investors. He believes Albemarle "is feeling contract price pressure" after his lithium industry contacts "show no improvement in sight." FMC CEO SELLS SHARES: On November 1, according to regulatory filings, Pierre Brondeau, the CEO lithium producer FMC, sold over $2.3M shares of company stock. PRICE ACTION: Shares of publicly traded companies with exposure to the lithium market are all down, with Albemarle down almost 1%, Sociedad Quimica y Minera de Chile S.A., or SQM, and Livent losing approximately 5%, and FMC down over 2%.

SQM

SQM

$23.75

-1.15 (-4.62%)

ALB

Albemarle

$64.60

-0.68 (-1.04%)

LTHM

Livent

$7.50

-0.325 (-4.15%)

FMC

FMC Corporation

$96.16

-2.175 (-2.21%)

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 21

    Nov

  • 22

    Nov

  • 05

    Dec

  • 06

    Dec

  • 12

    Dec

SQM SQM
$23.75

-1.15 (-4.62%)

08/23/19
BMOC
08/23/19
NO CHANGE
Target $24
BMOC
Market Perform
SQM price target lowered to $24 from $31 at BMO Capital
BMO Capital analyst Joel Jackson lowered his price target on SQM to $24 and kept his Market Perform rating to reflect his reduced price expectations for lithium and potassium nitrate. The analyst contends that the company's expected 2019 EBITDA of about $674M would represent its lowest earnings since 2009, and he expects minimal earnings growth next year given the management's focus on selling lithium "no matter the price". Jackson adds that SQM will remain challenged in lithium from higher supply than demand and continued mix issues.
08/26/19
SBSH
08/26/19
NO CHANGE
Target $25
SBSH
Neutral
SQM price target lowered to $25 from $33 at Citi
In a research note partially titled "Still Too Early," Citi analyst Andrew McCarthy lowered his price target for SQM to $25 from $33 and reiterates a Neutral rating on the shares. It remains too early to get more positive on the stock given the recent "weak" lithium market data and downward consensus earnings revisions ahead, McCarthy tells investors. He sees the stock as fairly valued at current levels.
08/22/19
JPMS
08/22/19
DOWNGRADE
Target $23
JPMS
Underweight
SQM downgraded to Underweight after lithium price forecast cut at JPMorgan
As previously reported, JPMorgan analyst Lucas Ferreira downgraded SQM to Underweight from Neutral after the company "once again" lowered its lithium price forecast citing significant exposure to the deteriorating Chinese market. He sees no short-term resistance to lithium carbonate prices given increasing supply, lower global economic growth and the weaker yuan, said Ferreira, who lowered his price target on SQM shares to $23 from $29.
08/22/19
08/22/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Toll Brothers (TOL) downgraded to Market Perform from Outperform at Wells Fargo with analyst Truman Patterson saying although the shares trade at roughly Book Value, he believes the equity lacks a catalyst over the near-to-intermediate term to drive outperformance. 2. SQM (SQM) downgraded to Underweight from Neutral at JPMorgan with analyst Lucas Ferreira citing significant exposure to the deteriorating Chinese market. 3. Fortis (FTS) downgraded to Neutral from Outperformer at CIBC. 4. Splunk (SPLK) downgraded to Neutral from Outperform at Baird with analyst Rob Oliver citing the company's meaningful OCF reduction that stems from the accelerating move to ratable business and reducing up-front invoice durations. 5. Hemispherx (HEB) downgraded to Hold from Buy at Maxim with analyst Jason McCarthy citing capital concerns. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ALB Albemarle
$64.60

-0.68 (-1.04%)

11/12/19
RBCM
11/12/19
DOWNGRADE
Target $71
RBCM
Sector Perform
Albemarle downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital analyst Arun Viswanathan downgraded Albemarle to Sector Perform from Outperform with a $71 price target.
11/12/19
RBCM
11/12/19
DOWNGRADE
Target $71
RBCM
Sector Perform
Albemarle downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital analyst Arun Viswanathan downgraded Albemarle to Sector Perform from Outperform with a price target of $71, down from $77. The analyst notes that with lithium prices falling below historical levels, global lithium suppliers may have to reduce output and wait for demand to catch up. Viswanathan adds that the near-term supply-demand imbalance, along with the general weakness in the auto industry, may keep Albemarle from achieving his previously forecast 40% or more EBITDA margins.
11/12/19
11/12/19
INITIATION

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. CSX (CSX) downgraded to Hold from Buy at Deutsche Bank. 2. Eaton (ETN) downgraded to Hold from Buy at HSBC. 3. Amneal Pharmaceuticals (AMRX) downgraded to Underweight from Neutral at JPMorgan with analyst Christopher Schott saying while some of the challenges facing the company appear fixable, like supply penalties and plant utilization, many appear fundamental, a function of the evolving dynamics in the U.S. generics market. 4. Albemarle (ALB) downgraded to Sector Perform from Outperform at RBC Capital with analyst Arun Viswanathan saying with lithium prices falling below historical levels, global lithium suppliers may have to reduce output and wait for demand to catch up. 5. Box (BOX) downgraded to Market Perform from Outperform at JMP Securities with analyst Erik Suppiger citing concerns that after the challenging October quarter, the pipeline of the company's business has slowed. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/13/19
SBSH
11/13/19
DOWNGRADE
Target $58
SBSH
Sell
Albemarle downgraded to Sell from Neutral at Citi
Citi analyst P.J. Juvekar downgraded Albemarle to Sell from Neutral with a price target of $58, down from $62. The analyst sees elevated inventory in lithium with ~30 kt of surplus carbonate inventory in China. Further, destocking could take another six months or more given "weak" China new electric vehicle sales on the June subsidy cut and the possibility of another subsidy cut in 2020, Juvekar tells investors in a research note. He believes Albemarle "is feeling contract price pressure" after his lithium industry contacts "show no improvement in sight."
LTHM Livent
$7.50

-0.325 (-4.15%)

05/16/19
ARGS
05/16/19
DOWNGRADE
ARGS
Hold
Livent downgraded to Hold from Buy at Argus
Argus analyst Bill Selesky downgraded Livent to Hold after its Q1 earnings last week, saying the management has forecasted weaker demand and pricing for its high-performance lithium hydroxide amid rising uncertainty around electric vehicle subsidies in China. The analyst further cites the company's forecast of no pricing recovery until late 2019 or early 2020 and its guidance cut, also lowering his FY19 EPS view to 61c from $1.09. Selesky maintains his forecast of FY20 EPS at $1.20 given his expectations for a rebound in lithium pricing.
08/12/19
BOFA
08/12/19
DOWNGRADE
Target $7
BOFA
Underperform
Livent downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill analyst Steve Byrne downgraded Livent to Underperform from Neutral and lowered his price target for the shares to $7 from $10. The stock has rallied 34% over the past three trading days despite reporting an inline Q2, Byrne tells investors in a research note. The analyst, however, believes the lithium hydroxide market for electric vehicles may not have enough growth to absorb the new capacity coming over the next 6-12 months. He sees increased risk that Livent's lithium hydroxide production will continue at "challenged economics."
05/22/19
LOOP
05/22/19
NO CHANGE
Target $12
LOOP
Buy
Livent has 'greater value' despite adverse 2019 dynamics, says Loop Capital
Loop Capital analyst Chris Kapsch kept his Buy rating and $12 price target on Livent after meeting with its management this week, saying that while the company's recent "reset" of 2019 EBITDA expectations was "disappointing", he sees the stock remaining supported by the lithium industry's longer-term growth story remaining intact. The analyst expects Livent to become a "more meaningful beneficiary" of the industry's "attractive and sustainable" annualized revenue growth rate of over 20% and, based on the management commentary, believes that an inflection in lithium fundamentals is coming next year.
10/23/19
GSCO
10/23/19
NO CHANGE
Target $85
GSCO
Buy
Buy Albemarle and Livent on 'compelling' contrarian call, says Goldman Sachs
The combination of sharp spot lithium price declines and elevated investor skepticism makes the setup for a contrarian call on shares of Albemarle (ALB) and Livent (LTHM) "compelling," Goldman Sachs analyst Robert Koort tells investors in a research note. The current negative sentiment and spot price plunge have run counter to Albemarle's fundamentals, where consensus estimates have remained relatively flat, adds the analyst. Koort believes lithium prices are approaching a bottom given limited cash margins for the marginal producers. This indicates investors "should dust off their lithium files and consider preparing for an upturn," contends the analyst. Despite lowering his price target for Albemarle to $85 from $96 and for Livent to $8.50 from $9.00, Koort sees "compelling value" in both Buy-rated names.
FMC FMC Corporation
$96.16

-2.175 (-2.21%)

10/31/19
BUCK
10/31/19
NO CHANGE
Target $105
BUCK
Buy
FMC Corporation price target raised to $105 from $100 at Buckingham
Buckingham analyst Dmitry Silversteyn raised his price target for FMC Corporation to $105 from $100 and reiterated a Buy rating, saying he sees significant upside following another beat and raise quarter driven by double-digit organic sales growth led by LATAM, India, China and Pakistan.
10/31/19
SBSH
10/31/19
NO CHANGE
Target $103
SBSH
Buy
Citi names FMC top pick in Ag, boosts target to $103 from $98
Citi analyst P.J. Juvekar raised his price target for FMC Corporation (FMC) to $103 from $98 saying the company reported "an all-round robust quarter," with growth across most geographies and segments. FMC is now the analyst's top pick in Agriculture, followed by Nutrien (NTR) then CF Industries (CF). He keeps a Buy rating on FMC. Ag chemicals is a better market than fertilizers, which tend to be commoditized, Juvekar tells investors in a research note.
10/16/19
10/16/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) upgraded to Neutral from Underweight at Atlantic Equities. 2. FMC Corporation (FMC) upgraded to Outperform from Neutral at Baird with analyst Ben Kallo saying he believes FMC's new product introductions, expected share gains in key markets, and operating leverage can drive revenue and adjusted EBITDA growth in 2020 and beyond. 3. Pure Storage (PSTG) upgraded to Outperform from Market Perform at Raymond James with analyst Simon Leopold saying recent VAR/Distributor checks have reflected positive sentiment suggesting Pure can exceed current Street estimates and he has gained a greater appreciation for the market expansion offered by the new FlashArray//C. 4. PDF Solutions (PDFS) upgraded to Buy from Hold at Craig-Hallum with analyst Christian Schwab saying PDF Solutions is transitioning the company to an analytics software model, and believes that looking out 3-5 years, and in line with management's long term model shared at the company's Analyst Day, it can become a "Rule of 40" SaaS like company with 70% gross margins and in aggregate a 20% top line growth rate and 20% operating margin. 5. Builders FirstSource (BLDR) and BMC Stock Holdings (BMCH) upgraded to Overweight from Equal Weight at Stephens. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/16/19
BARD
10/16/19
UPGRADE
Target $95
BARD
Outperform
Baird upgrades 'safe-haven' FMC Corporation to Outperform
As previously reported, Baird analyst Ben Kallo upgraded FMC Corporation to Outperform from Neutral with a price target of $95, up from $86. He believes FMC's new product introductions, expected share gains in key markets, and operating leverage can drive revenue and adjusted EBITDA growth in 2020 and beyond, Kallo tells investors. He also sees the company's free cash flow generation allowing it to return cash to shareholders and/or invest in growth, potentially via M&A, he said. Given that he believes FMC's growth is not as tied to the global business cycle as specialty chemical peers, Kallo thinks the stock could be a "safe-haven," he added.

TODAY'S FREE FLY STORIES

VERU

Veru

$4.19

0.07 (1.70%)

07:25
01/21/20
01/21
07:25
01/21/20
07:25
Recommendations
Veru analyst commentary  »

Veru price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUAN

Nuance

$19.74

-0.02 (-0.10%)

07:24
01/21/20
01/21
07:24
01/21/20
07:24
Hot Stocks
Nuance announces Dragon Medical One availability in France, Belgium, Netherlands »

Nuance Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 05

    Feb

MRSN

Mersana Therapeutics

$8.05

0.42 (5.50%)

07:23
01/21/20
01/21
07:23
01/21/20
07:23
Recommendations
Mersana Therapeutics analyst commentary  »

Mersana Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EOG

EOG Resources

$85.35

-1.66 (-1.91%)

07:22
01/21/20
01/21
07:22
01/21/20
07:22
Upgrade
EOG Resources rating change  »

EOG Resources upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

KMDA

Kamada

$6.62

0.09 (1.38%)

07:21
01/21/20
01/21
07:21
01/21/20
07:21
Hot Stocks
Kamada announces $25M private placement with FIMI Opportunity Fund »

Kamada announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LTHM

Livent

$8.90

0.05 (0.57%)

07:21
01/21/20
01/21
07:21
01/21/20
07:21
Downgrade
Livent rating change  »

Livent downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KVHI

KVH Industries

$10.91

0.05 (0.46%)

, LMT

Lockheed Martin

$425.62

-0.055 (-0.01%)

07:20
01/21/20
01/21
07:20
01/21/20
07:20
Hot Stocks
Lockheed Martin selects KVH fiber optic gyro for infrared search, track system »

KVH Industries (KVHI)…

KVHI

KVH Industries

$10.91

0.05 (0.46%)

LMT

Lockheed Martin

$425.62

-0.055 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

BIDU

Baidu

$139.64

0.2 (0.14%)

07:18
01/21/20
01/21
07:18
01/21/20
07:18
Recommendations
Baidu analyst commentary  »

Baidu price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

DIS

Disney

$144.25

-0.85 (-0.59%)

07:18
01/21/20
01/21
07:18
01/21/20
07:18
Hot Stocks
Disney+ moves up EMEA launch date to March 24 »

Disney's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Feb

RDHL

RedHill Biopharma

$6.16

0.11 (1.82%)

07:18
01/21/20
01/21
07:18
01/21/20
07:18
Hot Stocks
RedHill Biopharma discontinues promotion of Donnatal, EnteraGam »

RedHill Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSU

Kansas City Southern

$166.57

4.77 (2.95%)

07:17
01/21/20
01/21
07:17
01/21/20
07:17
Initiation
Kansas City Southern initiated  »

Benchmark starts Kansas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BGNE

BeiGene

$170.73

2.85 (1.70%)

07:16
01/21/20
01/21
07:16
01/21/20
07:16
Hot Stocks
BeiGene says Phase 3 trial of tislelizumab meets primary endpoint »

BeiGene announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

CSX

CSX

$76.36

-0.39 (-0.51%)

07:16
01/21/20
01/21
07:16
01/21/20
07:16
Initiation
CSX initiated  »

Benchmark doesn't…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PDD

Pinduoduo

$39.43

-0.07 (-0.18%)

07:15
01/21/20
01/21
07:15
01/21/20
07:15
Recommendations
Pinduoduo analyst commentary  »

Pinduoduo price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MA

MasterCard

$323.60

3.36 (1.05%)

07:15
01/21/20
01/21
07:15
01/21/20
07:15
Initiation
MasterCard initiated  »

MasterCard initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

V

Visa

$204.71

3.765 (1.87%)

07:14
01/21/20
01/21
07:14
01/21/20
07:14
Initiation
Visa initiated  »

Visa initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 30

    Jan

  • 11

    Feb

ETON

Eton Pharmaceuticals

$7.14

-0.3 (-4.03%)

07:14
01/21/20
01/21
07:14
01/21/20
07:14
Hot Stocks
Eton Pharmaceuticals, Xellia announce Biorphen co-promotion agreement »

Eton Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Mar

MYGN

Myriad Genetics

$28.71

-0.21 (-0.73%)

, AZN

AstraZeneca

$51.34

0.84 (1.66%)

07:13
01/21/20
01/21
07:13
01/21/20
07:13
Hot Stocks
Myriad Genetics submits sPMA for BRACAnalysis CDx as companion diagnostic »

Myriad Genetics (MYGN)…

MYGN

Myriad Genetics

$28.71

-0.21 (-0.73%)

AZN

AstraZeneca

$51.34

0.84 (1.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 06

    Feb

  • 13

    Feb

BABA

Alibaba

$227.41

3.53 (1.58%)

07:12
01/21/20
01/21
07:12
01/21/20
07:12
Recommendations
Alibaba analyst commentary  »

Alibaba price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

  • 13

    Feb

SWTX

SpringsWorks Therapeutics

$35.77

0.07 (0.20%)

07:12
01/21/20
01/21
07:12
01/21/20
07:12
Recommendations
SpringsWorks Therapeutics analyst commentary  »

SpringsWorks price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEGA

Pegasystems

$86.47

0.64 (0.75%)

07:12
01/21/20
01/21
07:12
01/21/20
07:12
Initiation
Pegasystems initiated  »

Pegasystems initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 05

    Mar

  • 10

    Mar

GTHX

G1 Therapeutics

$25.36

-0.42 (-1.63%)

07:11
01/21/20
01/21
07:11
01/21/20
07:11
Recommendations
G1 Therapeutics analyst commentary  »

G1 Therapeutics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QD

Qudian

$3.51

-0.035 (-0.99%)

07:11
01/21/20
01/21
07:11
01/21/20
07:11
Downgrade
Qudian rating change  »

Qudian downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AG

First Majestic

$10.53

-0.515 (-4.66%)

07:11
01/21/20
01/21
07:11
01/21/20
07:11
Hot Stocks
First Majestic to install HIG mill technology at San Dimas, La Encantada mines »

As a result of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

AG

First Majestic

$10.53

-0.515 (-4.66%)

07:10
01/21/20
01/21
07:10
01/21/20
07:10
Hot Stocks
First Majestic to invest $171.5M on capex in 2020 »

In 2020, the Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.